Clinical Challenges Facing Pharma Over the Next Five Years
Share on
With 2020 shaking up the pharma industry and ushering in a wealth of new technologies, ideas and processes, the future seems more uncertain than ever. Given the sheer number of new challenges and obstacles to overcome in the clinical sector, it can be difficult to know what to prioritise and which areas to face first. Proventa set out to find out more about the greatest challenges in ClinOps today.
Off the back of its’ successful 2020 Strategy Meetings for Clinical Operations experts, Proventa asked its more than 150 delegates what they thought were the most pressing challenges facing their companies today:
Joshua Neil, Editor
Proventa International
To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Clinical Operations Strategy Meetings, set for May, June and July 2021 respectively.
Another Direction for Clinical Oncology: Targeting the Anti-Inflammatory Response in Cancer
Approximately 15-20% of all cancer cases are preceded by infection, chronic inflammation, or autoimmunity at the same tissue or organ site. While inflammation is a natural response to tissue damage, chronic inflammation can become pathological. The role of inflammation in...
5 days agoAnother Direction for Clinical Oncology: Targeting the Anti-Inflammatory Response in Cancer
Approximately 15-20% of all cancer cases are preceded by infection, chronic inflammation, or autoimmunity at the same tissue or organ site. While inflammation is a natural response to tissue damage, chronic inflammation can become pathological. The role of inflammation in...
5 days ago
Targeted Protein Degradation: A Potential Tool for Discovering Druggable Targets
Drug discovery is the first step in therapeutic breakthroughs. Unfortunately, this cannot occur without target discovery - the identification and validation of druggable targets. Whether it be proteins or small molecules, discovering a ‘druggable’ biological target can be a challenge...
6 days agoTargeted Protein Degradation: A Potential Tool for Discovering Druggable Targets
Drug discovery is the first step in therapeutic breakthroughs. Unfortunately, this cannot occur without target discovery - the identification and validation of druggable targets. Whether it be proteins or small molecules, discovering a ‘druggable’ biological target can be a challenge...
6 days ago
Biobanks and EHR Data in Drug Design and Development
Over the last five years, drug design and development has evolved substantially with technological innovations. Electronic health records (EHRs) have played an important role in utilising health data on a digital platform in both preclinical and clinical studies. Biobanks have...
7 days agoBiobanks and EHR Data in Drug Design and Development
Over the last five years, drug design and development has evolved substantially with technological innovations. Electronic health records (EHRs) have played an important role in utilising health data on a digital platform in both preclinical and clinical studies. Biobanks have...
7 days agoInterested?
Reserve your space
